|  |  | 

India Top Headlines

Covaxin effective in the UK virus strain of Covid-19: ICMR | India News


NEW DELHI: An Indian Council for Medical Research (ICMR) study on Covaxin shows comparable neutralizing activity from individuals vaccinated against the UK variant strain.
The ICMR National Institute of Virology scientist performed the plaque reduction neutralization test using sera collected from 26 recipients of the Bharat Biotech coronavirus vaccine (COVAXIN) against the UK variant strain.
“A comparable neutralization activity of sera from vaccinated individuals shown against the UK variant and the heterologous strain with similar efficiency dispels the uncertainty of a possible neutralization leak,” stated the paper published in bioRxiv in a pre-printed version.
“We successfully isolated and characterized SARS-CoV-2 from UK returnees in India with all the characteristic mutations of the UK variant,” said the scientist from NIV-Pune.
“We present the neutralizing antibody (Nab) titers to underscore the efficacy of the candidate Covaxin vaccine against the UK variant of SARS-CoV-2 and one of the heterologous strains. Sera collected from 38 vaccine recipients, who received the Covaxin vaccine candidate in phase Trial II had NAb titers equivalent to the homologous strain and two heterologous strains with the characteristic UK variant substitution, “the authors said.
“The mean 50 percent neutralization ratio of the sera was found to be 0.8 and 0.9 compared to previously detected SARS CoV-2 strains against the UK mutant strain,” they said.
“Our study evidently highlighted the comparable neutralizing activity of sera from vaccinated individuals against variant and heterologous strains of SARS-CoV-2.”
“Importantly, sera from vaccine recipients could neutralize UK variant strains without taking into account the uncertainty about a potential escape. It was reassuring from the neutralizing antibody data generated in our lab that one might expect that indigenous Covaxin after its implementation in the vaccination program will work against the new UK variant. It is unlikely that the mutation could curb the potential benefits of the vaccine in question, “he said.
The ICMR scientist mentioned that they have reported the development of an inactivated whole virion vaccine against SARS-CoV-2 (Covaxin) that elicited a remarkable neutralizing antibody response in a phase I clinical trial against homologous and two heterologous strains of the group Not qualified.
In the phase II clinical trial, the candidate vaccine showed remarkable results with the plaque reduction neutralization test. The seroconversion rate with neutralizing antibodies after vaccination with Covaxin was 99.6%.
It is relevant to note that the rapid increase in SARS-CoV-2 cases due to variant of concern (VOC) in the United Kingdom (United Kingdom) raised concerns in several countries.

Times of India